Royalty Pharma to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B

Royalty Pharma to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B
Innoviva to acquire La Jolla Pharma for $149M including debt
Innoviva to acquire Entasis Therapeutics for $2.20/share
1.31BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US45781M1018
CUSIP
88338T104
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
7.83
PEG Ratio
2.80
Book Value
15.90
Dividend Share
-
Dividend Yield
-
Earnings Share
2.35
Wall Street Target Price
33.83
EPS Estimate Current Year
0.79
EPS Estimate Next Year
2.06
EPS Estimate Current Quarter
0.34
EPS Estimate Next Quarter
0.522
Most Recent Quarter
-
Revenue TTM
438,318,016
Gross Profit TTM
337,372,992
EBITDA
199,807,008
Profit Margin
44.13%
Return On Assets TTM
7.29%
Return On Equity TTM
18.02%
Revenue Per Share TTM
5.953
Qtly Revenue Growth YOY
-1.60%
Diluted Eps TTM
2.35
Qtly Earnings Growth YOY
590.40%
Trailing PE
7.83
Forward PE
8
Price Sales TTM
2.9855
Price Book MRQ
1.1504
Enterprise Value Revenue
2
Enterprise Value EBITDA
3
965.00
0.00%128.26
0.00%390.94
-2.36%151.52
-2.31%925.70
-1.93%32.39
-1.88%318.32
-1.17%516.11
-1.04%917.00
-0.91%199.30
-0.11%